Vivesto AB announced that the company's new permanent CEO Erik Kinnman will take up his position on January 23, 2023. Erik Kinnman has 27 years of experience from senior positions in Life Science, including AstraZeneca and Sobi, and has worked as a financial analyst at Danske Bank. He has been CEO for five years for Abliva, CEO of Sprint Bioscience for two years, and holds board member positions for Stayble and ISR. Erik has a background as a doctor specializing in neurology and pain management and is an associate professor at Karolinska Institutet.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3065 SEK | +2.17% | +1.16% | -24.79% |
Mar. 26 | Transcript : Vivesto AB - Special Call | |
Mar. 07 | Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.79% | 14.92M | |
+31.08% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+14.72% | 239B | |
+10.11% | 210B | |
-6.99% | 200B | |
+8.12% | 167B | |
-1.42% | 161B |
- Stock Market
- Equities
- VIVE Stock
- News Vivesto AB
- Vivesto AB Announces Appoints Erik Kinnman as CEO, Effective from January 23, 2023